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Abstract
Background: In the present study we have analyzed the mechanisms of calcium entry and
mobilization in platelets obtained from rats chronically treated with the nitric oxide synthesis
inhibitor, N-nitro L-arginine methyl ester [L-NAME, 40 mg/kg/day, 5 days). The platelets were
obtained the day of the experiment, washed and loaded with fura-2. The intracellular calcium levels
were determined in suspension of cells by means of fluorescence spectroscopy.
Results: Basal calcium levels were always elevated in the platelets of the L-NAME-treated rats,
both in the presence and in the absence of extracellular calcium. The administration of thrombin
in the absence and in the presence of extracellular calcium induced important elevations in calcium
levels that were always of greater magnitude in the platelets of the L-NAME-treated rats than in
those of the controls. The addition of calcium to thapsigargin-treated platelets produced a massive
elevation in calcium levels in both groups that was significantly greater in the platelets obtained
from the hypertensive rats than in those of the controls.
Conclusions: It is concluded that the arterial hypertension induced by the reduction of nitric
oxide alters the regulation of platelet calcium levels so that elevated baseline levels and calcium
entry and mobilization are enhanced. This could be the result of direct or indirect effects of the
lack of nitric oxide synthesis in platelets or in other tissues.
Background
Nitric oxide (NO) is a very important regulator of numer-
ous biological functions, among them the control of vas-
cular tone. The reduction of NO production, either by
inhibiting its synthesis or in situations of endothelial dys-
function, leads to arterial hypertension which then affects
hemostatic, vascular, renal, and cardiac function, among
others [1-3]. Arterial hypertension is also a risk factor for
developing thrombotic events, which is related to activa-
tion of blood platelets which then can interact easily with
a damaged vascular endothelium. It is thought that the
mechanism responsible for the activation of platelets in
hypertension is related to an increased cytosolic calcium
(Ca2+) level and to an enhanced sensitivity to agonists, but
the mechanisms responsible for this increase in platelet
Ca2+ are not known [4,5].
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gation of platelets. In fact, platelets were one of the first
cell types where the L-arginine-nitric oxide pathway was
characterized [6]. Recent studies have also suggested that
NO is able to interfere with the regulation of calcium lev-
els in platelets [7] and in other cell types. Thus, a NO-
induced reduction of intracellular calcium levels has been
demonstrated to occur both at the level of calcium entry
to the cell from the extracellular space and at intracellular
calcium release sites, such as the endoplasmic reticulum
[7]. Thus, we hypothesized that the reduction in NO levels
brought about by the chronic inhibition of NO that
induces an arterial hypertensive state would induce an ele-
vation in platelet calcium concentration. In order to test
this hypothesis, we have performed experiments on plate-
lets obtained from L-NAME-treated hypertensive rats, by
using fluorescence spectroscopy.
Results
Mean arterial pressure was increased in the L-NAME-
treated animals and averaged 154.3 ± 1.6 mmHg (n = 6).
This value was significantly different from that observed
in the control animals (105.6 ± 1.1, n = 6). Resting cal-
cium levels were always elevated in the platelets of the L-
NAME-treated rats, both in the presence (155 ± 10 nM in
these hypertensive rats and 76 ± 8 nM in the controls) and
in the absence of extracellular calcium (154 ± 7 nM and 70
± 4 nM, respectively). The administration of thrombin in
the absence of extracellular calcium (figure 1) induced a
sharp elevation in calcium levels and a decline back to
basal levels, which in the case of the two higher doses, 0.3
and 1 U, reached even values well below the baseline.
However, the AUC measured during the first 60 seconds
after the administration of the 0.3 U dose was significantly
greater in the platelets of the hypertensive rats (866.5 ±
102.4 units) than in those of the controls (513.53 ± 64.9
units). The AUC was not calculated in the experiments
with the dose of 1 U because calcium fell below baseline
during the first 15 seconds after the drug administration.
But, the lower dose of 0.1 U maintained calcium elevated
for the entire 180 seconds period and the AUC was again
significantly enhanced in the platelets of the hypertensive
rats (2727.9 ± 264.2 units) than in those of the controls
(1726.6 ± 223.6 units).
The administration of thrombin in the presence of 1 mM
extracellular calcium induced important elevations in cal-
cium levels that were maintained during the experiment
(figure 2), and that were always of greater magnitude in
the platelets of the L-NAME-treated rats than in those of
the controls, as it can be concluded from the AUC data
presented in figure 3.
Finally, thapsigargin administration to platelets in the
absence of extracellular calcium slightly elevated baseline
calcium levels, but without significant differences
between the groups (figure 4, left). However, the addition
of calcium to these thapsigargin-treated platelets pro-
duced a massive elevation in calcium levels in both
groups, that was significantly greater in the hypertensive
rats (area under the curve: 551.9 ± 32 units) than in the
controls (429.4 ± 25 units).
Discussion
Several studies indicate that arterial hypertension is asso-
ciated with alterations in the regulation of intracellular
calcium levels in many cell types of human and experi-
mental hypertension [3,4,8,9]. These alterations bring
about an elevation in cytosolic calcium levels which
seems to be related, among others, with an enhanced vas-
cular tone and with a tendency to platelet activation,
which contributes to thrombotic events. Also, platelets are
readily available and they share several alterations shown
by other cell types such as smooth muscle cells [8].
Because of this, platelets are often utilized for the study of
calcium signaling. In the present work, we have used
platelets to analyze the regulation of calcium levels in a
frequently utilized model of arterial hypertension, the L-
NAME-treated rat. This nitric oxide deficient arterial
hypertensive rat model is now very much studied because
it is very well suited to analyze the pathophysiology of
arterial hypertension.
As it is shown by the present data, platelets obtained from
the hypertensive rats exhibited greater calcium levels in
the resting state. Although platelet calcium levels have
been measured frequently in other arterial hypertensive
rat models, we believe this is the first demonstration of a
similar alteration in the L-NAME-treated hypertensive
model. Also, a similar alteration in free calcium concen-
tration has been described in red blood cells of rats chron-
ically treated with L-NAME [10]. This elevated resting level
of calcium may be the result of the alterations identified
in the present experiments, enhanced calcium entry and
mobilization, and likely to be the consequence of the def-
icit in NO synthesis. These results are in keeping from pre-
vious studies from our laboratory [11], showing that the
mesenteric vessels of L-NAME hypertensive rats show an
enhanced response to vasopressors which is related to cal-
cium entry.
The responses to the agonist thrombin were significantly
enhanced in the platelets of the hypertensive animals,
both in the absence and in the presence of calcium. When
thrombin was administered in the absence of external cal-
cium, the elevation in cytoplasmic calcium levels is the
result of calcium release from the internal stores, mainly
endoplamic reticulum, because of the production of IP3
and other metabolites produced after the signal transduc-
tion pathway has been started [12,13]. Interestingly, inPage 2 of 7
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thrombin, the calcium levels declined well below the
baseline levels and this may be indicative of an activation
of cell membrane calcium extrussion mechanisms, such as
the plasma membrane calcium ATP-ase [13]. When
thrombin is administered in the presence of extracellular
calcium, another mechanism of cellular calcium elevation
also takes place, the entry from the extracellular space, in
this case probably through store operated calcium chan-
nels, since calcium entry after thrombin is mainly capaci-
tative [12,13]. Our results clearly indicate that both
mechanisms, the entry from the extracellular space and
the mobilization from the internal stores, are working in
an exaggerated manner in the platelets of the L-NAME-
treated hypertensive rats, which results in much higher
calcium levels.
Another experiment was used to confirm that capacitative
calcium entry is altered in the platelets of the hypertensive
rats. Thus, we used thapsigargin to inhibit the uptake of
cytoplasmic calcium by the calcium ATP-ase of the endo-
plasmic reticulum. This effect brings about the opening of
the so-called store-operated calcium channels in the
plasma membrane, also called capacitative calcium entry.
As observed, when calcium was added after the adminis-
tration of the pump inhibitor, a massive entry of calcium
was observed and the effect was again significantly greater
in the platelets of the hypertensive rats.
It is very likely that at least part of these effects are due to
the absence of nitric oxide, an important regulator of the
intracellular calcium levels. Thus, it has been shown that
NO inhibits calcium influx indirectly via acceleration of
refilling of calcium stores [7]. If less NO is available as a
consequence of the inhibition of its synthesis, then cal-
cium influx would be increased, because of the lower
refilling of calcium stores. Another possibility is that NO
also interferes with the extrusion of calcium from the cell,
but this possibility has not been directly tested in the
present experiments. Thus, future investigations are
needed to clearly define the role of NO in these
alterations.
Conclusion
The arterial hypertension induced by the reduction of
nitric oxide levels alters the regulation of platelet calcium
levels so that elevated resting levels and an enhanced cal-
cium entry and mobilization are very evident. These alter-
ations may be due to direct or indirect effects of nitric
oxide interacting with the mechanisms controlling cal-
cium levels in platelets and in other tissues.
Methods
Male Sprague-Dawley rats born and raised in the Animal
House of the Universidad de Murcia were used in the
present study. All the experiments were performed accord-
ing to the ethical rules for the treatment of laboratory ani-
mals of the European Union.
Experimental groups
Animals weighing around 250 g were chronically treated
with the NO synthesis inhibitor, L-NAME (40 mg/kg/day
in the drinking water) for 5 days. The dose of the inhibitor
was adjusted daily according to the water intake and body
weight. Control animals were also concurrently main-
tained with no treatment. Normal rat chow was offered
with no restrictions. Blood pressure was determined by
the tail cuff method (Cibertec, Madrid, Spain) by using
MacLab software (AD Instruments, UK) in a Macintosh
LCII computer.
Obtention of platelets and fura-2 loading
Animals were anesthetized with thiobutabarbital (Inactin,
100 mg/kg, i.p., RBI, Massachussets, USA) and blood
obtained from the abdominal aorta in a plastic tube con-
taining an anticoagulant solution (composition in mM:
sodium citrate, 80; citric acid, 52; glucose, 180). After
obtaining platelet rich plasma (700 × g, 5 min), platelets
were pelleted (745 × g, 8 min) and resuspended in a low
pH-zero calcium buffer (buffer 1, composition in mM:
NaCl, 136; KCl, 2.7; MgCl2, 2; HEPES, 5; Glucose, 5.6;
NaH2PO4, 0.42; EGTA, 0.5, pH 6.6), also containing apy-
rase (40 µg/ml) and PGE1 (50 µM). After centrifugation
(745 × g, 8 min), platelets were resuspended in low-cal-
cium buffer (buffer 2, same composition as buffer 1,
except: CaCl2, 0.16 mM and no EGTA was added, pH 7.4).
Area under the curve of the integrated calcium responses aft r thrombin administration in the presence of extracellular calciumFigure 3
Area under the curve of the integrated calcium responses 
after thrombin administration in the presence of extracellular 
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with 2.5 µM fura-2 AM (Molecular Probes, Leiden, The
Netherlands) and same amount of pluronic acid 20% (in
DMSO). Fura-2 incubation was terminated by addition of
1 ml of buffer 1 and the tube centrifuged at 745 × g, 8 min.
After centrifugation, the supernatant was discarded and
the pellet of platelets resuspended in 1 ml of buffer 2 and
stored at room temperature and in the dark until calcium
measurements.
Calcium measurements
Platelets (100 µl + 1,9 ml of buffer 2) were placed in fluo-
rescence-free cuvettes (C-0793, Sigma) in the optical field
of a fluorescence spectrometer (Aminco Bowman 2,
Microbeam, Barcelona, Spain), under continuous stirring
and at 37°C. The cells were excited alternatively with light
of 340 and 380 nm wavelength and the light emitted at
510 nm collected once a second, stored and processed by
a PC-compatible computer equipped with a proprietary
software. The calibration of [Ca2+] was based on the signal
ratio at 340/380 nm and an established protocol as stated
below. The [Ca2+] was calculated according to the
formula:
[Ca2+] = ((R-Rmin)/(Rmax-R))·(Sf/Sb)·Kd
where R is the ratio of the 340/380 nm fluorescence sig-
nal. Rmax is the 340/380 ratio in the presence of saturating
calcium (0.5% Triton X-100 containing 1 mM CaCl2),
Rmin is the 340/380 ratio in calcium free buffer (EGTA-Tris
5 mM), Kd is the dissociation constant (225 nM), and Sf/
Sb is the ratio of the 380 nm fluorescence measured in
calcium free conditions to that in calcium repleted condi-
tions. Background fluorescence was obtained after
addition of MnCl2 (1 mM) and subtracted from every
value. All drugs and chemicals were added in small vol-
umes (less than 10 µl) to the cuvette, and the platelets
were not washed between drug additions. Only one con-
centration of each drug was tested in every platelets sus-
pension. During the time necessary for each experiment
(less than 5 minutes), the baseline did not change in a
control experiment without agonists. The calibration pro-
cedure was done in every experiment, to take into account
differences in the number of platelets between animals.
Experimental protocols
After obtaining baseline values for 30 seconds, the appro-
priate drug concentration was added and the fluorescence
recorded for 180 seconds. Then, the calibration procedure
(as stated above) was performed and the experiment was
finished. Platelets were studied in the presence (1 mM)
and in the absence of extracellular calcium (EGTA 0.5
mM) and were challenged by addition of thrombin (0.1,
0.3, and 1 units/ml). To analyze the capacitative mecha-
nism, platelets with no calcium added were tested with
Changes of intracellular calcium levels in response to thapsigargin in platelets from control and L-NAME hypertensive rats, in the absence of extracellul r calcium (left) and aft r addition of 1 mM ext rnal calcium (right)Figur  4
Changes of intracellular calcium levels in response to thapsigargin in platelets from control and L-NAME hypertensive rats, in 
the absence of extracellular calcium (left) and after addition of 1 mM external calcium (right). The data are the mean and stand-
ard error of 6 experiments. Only the mean is provided in the right panel, for the sake of clarity.Page 6 of 7
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thapsigargin (1 µM) for 3 min and then calcium (1 mM)
for another 3 min.
Drugs
Fura-2 AM was dissolved in DMSO. The rest of products
used were from Sigma Chemical (Madrid, Spain), except
where indicated. Drug stock solutions were prepared in
distilled water and maintained frozen (-20°C). Appropri-
ate dilutions were prepared freshly every day in buffer 2.
Statistical analysis
Data are expressed as the mean ± S.E. In order to compare
the calcium responses between control and experimental
rats, the area under the curve (AUC) of the individual cal-
cium responses were calculated by summation of all
experimental values (180 seconds) minus the averaged
baseline (30 seconds), and expressed as arbitrary units.
The resulting values as well as baseline values were com-
pared by one-way analysis of variance. A probability level
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